Log in to search using one of your social media accounts:

 

Medical News Today: More than just 'chemo brain': Cancer impacts memory, too
After chemotherapy, many people report experiencing 'chemo brain,' characterized by impaired cognitive function. But could cancer itself be to blame? (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - November 23, 2017 Category: Consumer Health News Tags: Cancer / Oncology Source Type: news

Chemo brain starts during cancer's progression, not just after chemotherapy
(Baycrest Centre for Geriatric Care) The memory and thinking problems experienced by cancer survivors, known as 'chemo brain' or 'chemo fog,' are not just the result of chemotherapy treatment, they may start as tumors form and develop, suggests a Baycrest-led study.Researchers found that female mice with a form of breast cancer demonstrated impaired performance on learning and memory tests before chemotherapy drugs were administered, according to recent findings published in the journal Neuroscience. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - November 21, 2017 Category: International Medicine & Public Health Source Type: news

Cancer treatment: Chemotherapy is particularly effective at fighting THIS deadly type
TESTICULAR CANCER symptoms are treated very effectively with chemotherapy, and scientists have just discovered why. (Source: Daily Express - Health)
Source: Daily Express - Health - November 20, 2017 Category: Consumer Health News Source Type: news

French Oncologists Upgrade Mesothelioma Standard of Care
Oncologists throughout France have joined the U.S.-based National Comprehensive Cancer Network (NCCN) in upgrading their recommended standard-of-care treatment regimen for unresectable pleural mesothelioma. Both groups have added bevacizumab (Avastin) to the traditional cisplatin and pemetrexed chemotherapy combination, expecting to see longer patient survival. “This is a major advancement for the care of mesothelioma patients,” Dr. Gerard Zalcman, head of thoracic oncology at Bichat-Claude Bernard Hospital, told Asbestos.com. “Clearly, this drug can change the natural history of this tumor.” Bevaci...
Source: Asbestos and Mesothelioma News - November 20, 2017 Category: Environmental Health Authors: Daniel King Tags: American Society of Clinical Oncology Avastin bevacizumab Bichat-Claude Bernard Hospital French Cooperative Thoracic Intergroup Gerard Zalcman National Comprehensive Cancer Network nintedanib Ofev pleural mesothelioma chemotherapy Source Type: news

Roche Cancer Drug Rises To Challenge Merck, Bristol-Myers
Tecentriq, a cancer immunotherapy developed by the Swiss drug giant Roche, slowed the progression of previously untreated lung cancer in a large clinical trial when combined with a chemotherapy regimen, the drug giant said. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - November 20, 2017 Category: Pharmaceuticals Authors: Matthew Herper, Forbes Staff Tags: OTC:RHHBY NYSE:MRK NYSE:BMY NYSE:AZN Source Type: news

Phase III IMpower150 study showed Roche ’s TECENTRIQ (atezolizumab) and Avastin (bevacizumab) plus chemotherapy significantly reduced the risk of disease worsening or death in the initial treatment of people with a type of advanced lung cancer
Roche today announced that the Phase III IMpower150 study met its co-primary endpoint of progression-free survival (PFS) and demonstrated that the combination of TECENTRIQ ® (atezolizumab) and Avastin® (bevacizumab) plus chemotherapy (paclitaxel and carboplatin) provided a statistically significant and clinically meaningful reduction in the risk of disease worsening or death (PFS) compared to Avastin plus chemotherapy in the first-line treatment of people with advan ced non-squamous non-small cell lung cancer (NSCLC). Initial observations for the co-primary endpoint of overall survival (OS) are encouraging. These d...
Source: Roche Investor Update - November 20, 2017 Category: Pharmaceuticals Source Type: news

Phase III IMpower150 study showed Roche ’s TECENTRIQ (atezolizumab) and Avastin (bevacizumab) plus chemotherapy significantly reduced the risk of disease worsening or death in the initial treatment of people with a type of advanced lung cancer
Roche today announced that the Phase III IMpower150 study met its co-primary endpoint of progression-free survival (PFS) and demonstrated that the combination of TECENTRIQ ® (atezolizumab) and Avastin® (bevacizumab) plus chemotherapy (paclitaxel and carboplatin) provided a statistically significant and clinically meaningful reduction in the risk of disease worsening or death (PFS) compared to Avastin plus chemotherapy in the first-line treatment of people with advan ced non-squamous non-small cell lung cancer (NSCLC). Initial observations for the co-primary endpoint of overall survival (OS) are encouraging. These d...
Source: Roche Media News - November 20, 2017 Category: Pharmaceuticals Source Type: news

FDA approves Roche ’s Gazyva for previously untreated advanced follicular lymphoma
Roche announced today that the US Food and Drug Administration (FDA) approved Gazyva ® (obinutuzumab) in combination with chemotherapy, followed by Gazyva alone in those who responded, for people with previously untreated advanced follicular lymphoma (stage II bulky, III or IV). The approval is based on results from the phase III GALLIUM study, which showed superior progression-fre e survival (PFS) for patients who received this Gazyva-based regimen compared with those who received a Rituxan® (rituximab)-based regimen as an initial (first-line) therapy. Follicular lymphoma, the most common slow-growing (indolent) f...
Source: Roche Investor Update - November 17, 2017 Category: Pharmaceuticals Source Type: news

FDA approves Roche ’s Gazyva for previously untreated advanced follicular lymphoma
Roche announced today that the US Food and Drug Administration (FDA) approved Gazyva ® (obinutuzumab) in combination with chemotherapy, followed by Gazyva alone in those who responded, for people with previously untreated advanced follicular lymphoma (stage II bulky, III or IV). The approval is based on results from the phase III GALLIUM study, which showed superior progression-fre e survival (PFS) for patients who received this Gazyva-based regimen compared with those who received a Rituxan® (rituximab)-based regimen as an initial (first-line) therapy. Follicular lymphoma, the most common slow-growing (indolent) f...
Source: Roche Media News - November 17, 2017 Category: Pharmaceuticals Source Type: news

Stage III CRC: Which Patients Need 6 Months of Adjuvant Chemo? Stage III CRC: Which Patients Need 6 Months of Adjuvant Chemo?
At the ESMO 2017 Congress in Madrid, Drs Sobrero and Taieb discuss the optimal duration of adjuvant chemotherapy for stage III colon cancer.Medscape Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 16, 2017 Category: Consumer Health News Tags: Hematology-Oncology Commentary Source Type: news

Thousands to benefit as 'breakthrough' breast cancer drugs approved for NHS use
Annually, 8,000 women in England with previously untreatable advanced breast cancer will have access to drugs shown to slow disease ’s progressionThousands of women with previously untreatable breast cancer will have access to two “breakthrough” drugs that have been approved for NHS use.The drugs, called palbociclib and ribociclib, have been shown to slow the progression of advanced cancer by at least 10 months and can delay the need for chemotherapy, giving women the chance to live a normal life for longer. In new draft guidance, the National Institute for Health and Care Excellence (Nice) has approved t...
Source: Guardian Unlimited Science - November 16, 2017 Category: Science Authors: Hannah Devlin Tags: Breast cancer Health Society Science The National Institute for Health and Care Excellence (Nice) NHS Drugs Source Type: news

'Breakthrough' breast cancer drugs get NHS approval
Research shows the two new treatments can slow the cancer down and delay the need for chemotherapy. (Source: BBC News | Health | UK Edition)
Source: BBC News | Health | UK Edition - November 16, 2017 Category: Consumer Health News Source Type: news

Quality of care for older Texas patients with colon cancer on the rise, still room for improvement
(University of Texas M. D. Anderson Cancer Center) Research from The University of Texas MD Anderson Cancer Center finds adherence to surgical treatment guidelines has improved significantly among older Texas patients with colon cancer since 2001, while adherence to chemotherapy guidelines has remained largely unchanged. The study, published today in Cancer, identifies factors influencing adherence rates, including socioeconomic status and access to skilled physicians. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - November 15, 2017 Category: Cancer & Oncology Source Type: news

Developing new molecular methods for synthetizing treatments for drug-resistant cancers
(Worcester Polytechnic Institute) With a $1.7 million award from the National Institutes of Health (NIH), Anita Mattson, a biochemist at Worcester Polytechnic Institute (WPI), will develop a new class of catalysts that could make it possible to reliably synthesize organic compounds that hold the promise of treating cancers that have become resistant to commonly used chemotherapy medications. The catalysts may also open the door to a new approach to discovering new drugs for cancer and many other diseases. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - November 15, 2017 Category: Cancer & Oncology Source Type: news

Jax company starts trial on cancer-fighting therapy
Jacksonville-based TapImmune Inc. (Nasdaq: TPIV) has enrolled its final patient in a randomized, Phase 2 clinical study of an immunotherapy that targets breast cancer. TapImmune's therapies help the body's immune system find and fight cancer, which has evolved to hide from and suppress it, CEO Peter Hoang previously told the Business Journal. This approach is outside of the box of traditional treatment methods like surgery, chemotherapy and radiation therapy tha t shut-down pathways for cancer to… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - November 14, 2017 Category: American Health Authors: Will Robinson Source Type: news

Cornell study reveals why testicular cancer is so responsive to chemo
(Cornell University) Cornell researchers have taken a major step toward answering a key question in cancer research: Why is testicular cancer so responsive to chemotherapy, even after it metastasizes? (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - November 14, 2017 Category: International Medicine & Public Health Source Type: news

Analysis of suicide risk in patients with penile cancer and review of the literature - Simpson WG, Klaassen Z, Jen RP, Hughes WM, Neal DE, Terris MK.
The treatment for penile cancer has been shown to cause harmful psychiatric symptoms as well as have detrimental effects on well-being. In the past several years, alternatives to total or partial penectomy have emerged, such as chemotherapy, radiation, pen... (Source: SafetyLit)
Source: SafetyLit - November 13, 2017 Category: International Medicine & Public Health Tags: Suicide and Self-Harm Source Type: news

Nano-targeting treatment for prostate cancer
(American Association of Pharmaceutical Scientists) Metastatic or castrate-resistant prostate cancer can spread to the bone in certain patients. While several new treatments are available, they can have a difficult time reaching the bone and can result in missing the metastatic lesions. New research presented today at the 2017 American Association of Pharmaceutical Scientists (AAPS) Annual Meeting and Exposition seeks to address this challenge with the development of a bone-targeted nanoparticle (NP) that delivers the chemotherapy drug cabazitaxel directly to the bone. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - November 13, 2017 Category: Cancer & Oncology Source Type: news

Amgen And Allergan Receive Positive CHMP Opinion For ABP 215 (Biosimilar Bevacizumab) For The Treatment Of Certain Types Of Cancer
First Avastin® (Bevacizumab) Biosimilar Candidate Recommended for European Approval THOUSAND OAKS, Calif., Nov. 10, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and Allergan plc. (NYSE:AGN) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for the Marketing Authorization of ABP 215, a biosimilar to Avastin® (bevacizumab). ABP 215 has been recommended for approval for the treatment of certain types of cancer, including in combination with fluoropyrimidine-based chemotherapy for metastatic carcinoma of the colon or rec...
Source: Amgen News Release - November 10, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Antioxidant-rich tea OMGTea could help beat cancer
EXCLUSIVE: Katherine Swift, 45, from Brighton, was inspired to set up OMGTea following the news that her mother Elizabeth had stage 3 breast cancer and was facing chemotherapy. (Source: the Mail online | Health)
Source: the Mail online | Health - November 10, 2017 Category: Consumer Health News Source Type: news

FDA Approves Cinvanti (aprepitant) Injectable Emulsion for the Prevention of Acute and Delayed Chemotherapy-Induced Nausea and Vomiting (CINV)
SAN DIEGO--(BUSINESS WIRE)--Nov. 9, 2017-- Heron Therapeutics, Inc. (Nasdaq: HRTX) (the Company or Heron), a commercial-stage biotechnology company focused on developing novel, best-in-class treatments to address some of the most important unmet... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - November 9, 2017 Category: Drugs & Pharmacology Source Type: news

Ivory Coast boy with cancerous tumour has chemotherapy
Kambou Sie, from the Ivory Coast, has suffered with the life-threatening condition since he was 11. He said his mother 'stopped caring' about him and left while his poor could not afford help. (Source: the Mail online | Health)
Source: the Mail online | Health - November 9, 2017 Category: Consumer Health News Source Type: news

How cells detect, mend DNA damage may improve chemotherapy
(Washington University School of Medicine) Human cells have a way of detecting and mending DNA damage caused by some common chemotherapy drugs, according to a new study from Washington University School of Medicine in St. Louis. The findings could have important implications for treating cancer. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - November 8, 2017 Category: Cancer & Oncology Source Type: news

Medical News Today: Cancer cells destroyed in just 3 days with new technique
Researchers reveal how altering the structure of chromatin in cancer cells could make them vulnerable to chemotherapy and other treatments. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - November 7, 2017 Category: Consumer Health News Tags: Cancer / Oncology Source Type: news

Q & amp;A: How to Prepare for an AI-Driven Future
For years the role of robotics and artificial intelligence within the realm of medtech has been hyped as the future of innovation and device development. Now that technological advances are beginning to catch up to our imagination, how will advanced robotic and AI technologies begin to reshape the medtech landscape?  Srihari Yamanoor With advances in machine learning and robotic design, artificial intelligence is poised to have a dramatic impact on the medical device field. With innovative opportunities on both the diagnostic and therapeutic sides of medicine, AI technologies could be the key that unlocks...
Source: MDDI - November 7, 2017 Category: Medical Devices Authors: Kristopher Sturgis Tags: BIOMEDevice San Jose Assembly and Automation Digital Health Source Type: news

Toxic for generations: Kids born to chemo survivors are increasingly infertile, having 72% fewer children
(Natural News) What are the generational health effects caused by chemotherapy? Precisely, which genes are turned on and off when a cancer patient is inundated with these toxic chemical agents? Do the chemotherapy-inflicted epigenetic changes pass on to the offspring of the patient and how do these changes impact fertility for future generations? Chemotherapy has lasting... (Source: NaturalNews.com)
Source: NaturalNews.com - November 6, 2017 Category: Consumer Health News Source Type: news

Fighting Neuroblastoma Like a Superhero
Treatment TermsNeuroblastoma CategoriesChildren's health Author Aliza Inbari Overview VG stands for Vomit Girl, the superhero that Sarah Smith created in her mind when she was a young child undergoing numerous rounds of chemotherapy to treat neuroblastoma, a childhood cancer that develops in the adrenal glands. Hero Imagevg_01.jpg Preview Image Content Blocks Content“Chemotherapy causes patients to vomit frequently so I came up with a superhero for myself: Vomit Girl,” explained Sarah, now a 22-year-old, cancer-free college student. Her best friend’s mom made her a large cape displaying the ...
Source: dukehealth.org: Duke Health News - November 6, 2017 Category: Consumer Health News Authors: dg62 at duke.edu Source Type: news

New research targets cancer's 'Achilles' Heel'
(Northwestern University) Northwestern Engineering's Vadim Backman has developed an effective new strategy for treating cancer that prevents cancer from evolving to withstand treatment, making the disease an easier target for existing drugs. If the cells cannot evolve to resist chemotherapy, for example, they die. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - November 6, 2017 Category: Cancer & Oncology Source Type: news

What Causes White Nails?
Discussion The nail matrix covers the area of the nail plate, and extends proximally in a crescent moon shape with the edges of the crescent extending proximally and inferiorly toward the underlying bone. The nail matrix is a multilayered epithelium that physiologically produces keratinization and gives rise to the nail plate. The distal matrix forms the lower 2/3s of the nail plate and the proximal matrix forms the upper 1/3 of the nail plate. the thickness of the nail plate is proportion to the matrix’s thickness. The nail plate’s free edge contour follows the shape of the nail’s lunula. Melanocytes occ...
Source: PediatricEducation.org - November 6, 2017 Category: Pediatrics Authors: pediatriceducationmin Tags: Uncategorized Source Type: news

FDA Cautions Cancer Patients About Medical Marijuana
The U.S. Food and Drug Administration (FDA) issued a stern warning Wednesday to companies marketing medical marijuana to cure or inhibit cancer — including mesothelioma — and cautioned patients about unsubstantiated claims. The FDA sent warning letters to four particular companies, citing deceptive marketing in violation of the Federal Food, Drug and Cosmetic Act. “We don’t let companies market products that deliberately prey on sick people with baseless claims that their substance can shrink or cure cancer,” said FDA Commissioner Scott Gottlieb in a press release Wednesday. “And we&rsqu...
Source: Asbestos and Mesothelioma News - November 2, 2017 Category: Environmental Health Authors: Walter Pacheco Tags: FDA marijuana warning marijuana for cancer medical marijuana for cancer Source Type: news

Are You Sure That's What the Doctor Said About Your Leukemia?
THURSDAY, Nov. 2, 2017 -- The stress of a frightening leukemia diagnosis may impede clear doctor-patient communication, a new study suggests. Patients undergoing chemotherapy treatment for acute myeloid leukemia (AML) tend to view their illness and... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - November 2, 2017 Category: General Medicine Source Type: news

Do Rising Cancer Drug Prices Warrant Regulation?
Source: HealthDay Related MedlinePlus Pages: Cancer Chemotherapy, Medicines (Source: MedlinePlus Health News)
Source: MedlinePlus Health News - November 1, 2017 Category: Consumer Health News Source Type: news

Chemotherapy 'may damage fertility of patients' children'
Researchers based at the University of Utah in Salt Lake City tested whether receiving chemotherapy was damaging to the fertility of children of chemotherapy patients. (Source: the Mail online | Health)
Source: the Mail online | Health - November 1, 2017 Category: Consumer Health News Source Type: news

Brain tumour's 'addiction' to common amino acid could be its weakness
(Queen Mary University of London) Starving a childhood brain tumour of the amino acid glutamine could improve the effect of chemotherapy, according to an early study led by Queen Mary University of London (QMUL) and funded by Children with Cancer UK and the Medical Research Council. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - November 1, 2017 Category: Cancer & Oncology Source Type: news

Doctors: When the Doctor ’ s Mother Has Cancer
I braced myself for what would come next: The beginning of every cancer story, when the seemingly innocent cough or dizziness takes a sinister turn. (Source: NYT Health)
Source: NYT Health - October 31, 2017 Category: Consumer Health News Authors: MIKKAEL A. SEKERES, M.D. Tags: Lung Cancer Tests (Medical) Brain Cancer Computerized Axial Tomography (CAT Scans) Leukemia Surgery and Surgeons Lymph Nodes and Lymphatic System Chemotherapy Radiation Source Type: news

New Study Shows Improved Peritoneal Mesothelioma Survival
Patients with malignant peritoneal mesothelioma who completed a novel, two-stage cytoreduction and intraperitoneal chemotherapy regimen had a median overall survival of 6.65 years. Almost 30 percent of those patients had a survival estimate of more than 10 years after the second stage of treatment, according to a study published recently in the Annals of Surgical Oncology. The study involved 113 patients from New York-Presbyterian Hospital/Columbia University Medical Center. Researchers demonstrated the therapeutic advances concerning this once unbeatable cancer. While progress has been slow in improving current pleural me...
Source: Asbestos and Mesothelioma News - October 31, 2017 Category: Environmental Health Authors: Walter Pacheco Tags: Columbia University Medical Center Dr. Michael Kluger Dr. Paul Sugarbaker HIPEC for peritoneal mesothelioma New York-Presbyterian Hospital peritoneal mesothelioma treatment Source Type: news

Cancer treatment side effects: Coping with diarrhoea, constipation and acid indigestion
Author KAREN McMILLAN and chef SAM MANNERING reveal how to deal with the side effects of chemotherapy. (Source: Daily Express - Health)
Source: Daily Express - Health - October 31, 2017 Category: Consumer Health News Source Type: news

Anatomics ’ custom 3D-printed sternum implant used in US 1st replacement procedure
Anatomics said this month that a custom 3D-printed implant it created was successfully implanted to replace the sternum and partial ribcage of a 20-year old patient who had lost significant bone mass to Chondrosarcoma, touting the procedure as a 1st for the US. The implant was composed of composite titanium and porous polyethylene designed using high-resolution CT scans of the patient’s chest, approved by an operating surgeon. The implant was only the 2nd of its kind to use the company’s PoreStar technology, though Anatomics has been innovating in the field of 3D printing for over 2 decades. Anatomics has been ...
Source: Mass Device - October 27, 2017 Category: Medical Devices Authors: Fink Densford Tags: Implants Research & Development Surgical anatomics Source Type: news

FDA Approves Intravenous Version of Tesaro Drug for Chemotherapy Nausea FDA Approves Intravenous Version of Tesaro Drug for Chemotherapy Nausea
Tesaro Inc said on Wednesday that the U.S. Food and Drug Administration approved an intravenous version of its drug to treat chemotherapy-induced nausea and vomiting in adults.News Alerts (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 27, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news

The top 10 medical disruptors of 2018
[Image from unsplash.com]Each year the Cleveland Clinic determines what the top 10 disruptors in healthcare will be for the following year. The criteria to be considered a disruptor or innovation is that it has to be innovative and could change care in a significant way in the next year. Approximately 150 to 200 Cleveland Clinic physicians from each of the institutes are interviewed for their suggestions of the top 10 innovations they think will be a disruptor. Venture capitalists and members of the media also get surveyed to consider the top innovation of the next year. From the large list, 300 to 400 suggestions are...
Source: Mass Device - October 26, 2017 Category: Medical Devices Authors: Danielle Kirsh Tags: Cardiovascular Diabetes Diagnostics Hospital Care Implants mHealth (Mobile Health) Neuromodulation/Neurostimulation Oncology Patient Monitoring Pharmaceuticals Regenerative Medicine Artificial pancreas Cancer cholesterol Clevel Source Type: news

Cancer patients diagnosed early ‘more likely to avoid chemo’
Cancer patients diagnosed early are far more likely to avoid chemotherapy than those with tumours found at a later stage, according to a major new study based on NHS data. (Source: Nursing Times)
Source: Nursing Times - October 26, 2017 Category: Nursing Source Type: news

FDA accepts Roche ’s supplemental Biologics License Application for Avastin as a front-line treatment for women with advanced ovarian cancer
Roche announced today that the U.S. Food and Drug Administration (FDA) has accepted the company's supplemental Biologics License Application (sBLA) for Avastin ® (bevacizumab) in combination with chemotherapy (carboplatin and paclitaxel), followed by Avastin alone, for the front-line treatment of women with advanced ovarian cancer. (Source: Roche Investor Update)
Source: Roche Investor Update - October 26, 2017 Category: Pharmaceuticals Source Type: news

FDA approves intravenous version of Tesaro drug for chemotherapy nausea
(Reuters) - Tesaro Inc said on Wednesday that the U.S. Food and Drug Administration approved an intravenous version of its drug to treat chemotherapy-induced nausea and vomiting in adults. (Source: Reuters: Health)
Source: Reuters: Health - October 25, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

Medical Marijuana Reduces CINV, Seizures in Children Medical Marijuana Reduces CINV, Seizures in Children
Medical marijuana helped reduce seizures and chemotherapy-related nausea and vomiting in children and adolescents, a study found.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - October 25, 2017 Category: Consumer Health News Tags: Pediatrics News Source Type: news

Tesaro Announces U.S. FDA Approval of Varubi IV for Delayed Nausea and Vomiting Associated With Cancer Chemotherapy
WALTHAM, Mass., Oct. 25, 2017 (GLOBE NEWSWIRE) -- Tesaro, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has approved Varubi (rolapitant) IV in combination with... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - October 25, 2017 Category: Drugs & Pharmacology Source Type: news

Medical News Today: All you need to know about hyperchloremia
We look at hyperchloremia, where a high level of chloride in the blood causes an electrolyte imbalance. Included is detail on the relation to chemotherapy. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - October 24, 2017 Category: Consumer Health News Tags: Blood / Hematology Source Type: news

Award-Winning Journalist And Cancer Survivor Joan Lunden Partners With Amgen To Launch 'At Home With Joan' To Empower Patients Battling Cancer
Unique Campaign Highlights the Importance of Understanding Your Treatment and Building a Support Community, With Advice From Joan Lunden, Cancer Survivors and Healthcare Professionals Campaign Encourages Patients to Advocate for Themselves When Facing Strong Chemotherapy and Associated Risks THOUSAND OAKS, Calif., Oct. 24, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the launch of At Home with Joan, a campaign led by breast cancer survivor and advocate Joan Lunden. This campaign aims to empower patients diagnosed with cancer to be active participants in their treatment plan in order to understand an...
Source: Amgen News Release - October 24, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news